Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18316826 | 1.00 | HCAR3 (0.44) | HCAR3KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL20956800 | 0.86 | HCAR3 (0.45) | HCAR3KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL18316881 | 0.85 | LMNA (0.43) | HCAR3KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL18316887 | 0.84 | HCAR3 (0.44) | HCAR3KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL18316884 | 0.84 | HCAR3 (0.44) | HCAR3KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL15573920 | 0.83 | POLB (0.48) | KMT2AALDH1A1L3MBTL1MEN1MAPK1 | |
| SCHEMBL15573917 | 0.83 | POLB (0.48) | KMT2AALDH1A1L3MBTL1MEN1MAPK1 | |
| SCHEMBL15575524 | 0.82 | HCAR3 (0.49) | HCAR3KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL15575526 | 0.82 | HCAR3 (0.49) | HCAR3KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL15575980 | 0.82 | HCAR3 (0.49) | HCAR3KMT2AALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932329-B2 | Benzimidazole derivatives as RLK and ITK inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160368908-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK AND ITK INHIBITORS | PRINCIPIA BIOPHARMA, INC. | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368908-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK AND ITK INHIBITORS | ITK, BLK, LMTK2 | HCAR3 2798/4885KMT2A 3603/4885ALDH1A1 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.